Tolebrutinib Trials Paused Over Safety Concerns & Setback for MS Spasticity Treatment episode artwork

EPISODE · Jul 22, 2022 · 9 MIN

Tolebrutinib Trials Paused Over Safety Concerns & Setback for MS Spasticity Treatment

from MS News & Perspectives · host MS News Today

Multiple Sclerosis News Today’s multimedia associate, Price Wooldridge, discusses how new U.S. enrollments in Phase 3 trials of tolebrutinib for MS have been paused due to some reports of liver injury.He also reads “Trial Results a Setback for US Approval of Nabiximols for MS Spasticity” from Ed Tobias’ column “The MS Wire.”=================================== Are you interested in learning more about multiple sclerosis? If so, please visit:https://multiplesclerosisnewstoday.com/ =====================================To join in on conversations regarding multiple sclerosis, please visit:https://multiplesclerosisnewstoday.com/forums/

Episode metadata supplied by the publisher feed · Published Jul 22, 2022

Embed this episode

NOW PLAYING

Tolebrutinib Trials Paused Over Safety Concerns & Setback for MS Spasticity Treatment

0:00 9:03

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

No similar episodes found.

No similar podcasts found.

Frequently Asked Questions

How long is this episode of MS News & Perspectives?

This episode is 9 minutes long.

When was this MS News & Perspectives episode published?

This episode was published on July 22, 2022.

Can I download this MS News & Perspectives episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.
URL copied to clipboard!